S.L.E. Lupus Foundation Board Member Tapped to Consult on New Clinical Trial
The LRI and S.L.E. Lupus Foundation congratulate Dr. Daniel Wallace on his appointment as consultant to XTL Biopharmaceuticals Ltd. for the planned Phase II trial for the Company's hCDR1 compound for lupus. Dr. Wallace serves on the Boards of the S.L.E. Lupus Foundation Board and the Lupus Research Institute. He founded Lupus LA, a member of the Lupus Research Institute National Coalition.
"Dr. Wallace and Dr. Urowitz are at the forefront of searching for viable treatment options for Lupus patients, and are respected, well known industry experts," said Josh Levine, CEO of XTL. "We are excited to welcome these clinicians aboard the XTL team, gaining access to their experience as it relates to trial design, dosing and other aspects of the drug development process for our Phase IIb Lupus trial. We believe that their involvement will be of great value to XTL throughout the entire trial process." Full Press Release